Viridian Therapeutics, Inc.\DE (VRDN) EPS (Weighted Average and Diluted): 2020-2025
Historic EPS (Weighted Average and Diluted) for Viridian Therapeutics, Inc.\DE (VRDN) over the last 6 years, with Sep 2025 value amounting to -$22.96.
- Viridian Therapeutics, Inc.\DE's EPS (Weighted Average and Diluted) rose 61.08% to -$22.96 in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.13, marking a year-over-year increase of 50.31%. This contributed to the annual value of -$204.82 for FY2024, which is 21.43% up from last year.
- According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's EPS (Weighted Average and Diluted) is -$22.96, which was up 65.73% from -$66.99 recorded in Q2 2025.
- Over the past 5 years, Viridian Therapeutics, Inc.\DE's EPS (Weighted Average and Diluted) peaked at -$0.71 during Q4 2021, and registered a low of -$256.73 during Q4 2023.
- Over the past 3 years, Viridian Therapeutics, Inc.\DE's median EPS (Weighted Average and Diluted) value was -$51.64 (recorded in 2024), while the average stood at -$55.72.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 97.19% in 2021, then tumbled by 24,991.55% in 2022.
- Over the past 5 years, Viridian Therapeutics, Inc.\DE's EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.71 in 2021, then crashed by 24,991.55% to -$178.15 in 2022, then crashed by 44.11% to -$256.73 in 2023, then spiked by 78.87% to -$54.24 in 2024, then skyrocketed by 61.08% to -$22.96 in 2025.
- Its last three reported values are -$22.96 in Q3 2025, -$66.99 for Q2 2025, and -$57.94 during Q1 2025.